Randomized trial: Bamlanivimab associated with Etesevimab reduce the viral load in patients with mild to moderate COVID-19
25 Jan, 2021 | 01:36h | UTCEditorial: Neutralizing Monoclonal Antibody for Mild to Moderate COVID-19
Editorial: Neutralizing Monoclonal Antibody for Mild to Moderate COVID-19